Results
Introduction

Objectives
Assessment of economic impact of defibrotide treatment and perspectives to regulate prescriptions to reduce costs were purposed for the 37 hospitals of the Public Assistance-Hospitals of Paris (AP-HP).
Aware of economic impact, experts have initiated a change of practice and they recommend a restrictive use of defibrotide specially limitation the off-label use in preventive (only patients with very high risk of VOD).
Conclusion
Experts recommended defibrotide use in prevention after considering alternatives, only in high risk situations defined by consensus, an improvement of pre-transplant cares (reduction of the liver damage and conditioning regimen intensity), an optimization of vials numbers per patient (centralized preparations, limitation of treatment duration). showed decreasing amounts which could be explained by a self-regulation of prescribers in front of the economic impact and practices changes.
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1. The part attributed to drugs cover a small part of treatment cost (97,524€ for an adult). 
